Condition: NSCLC (Non-small Cell Lung Cancer) · Solid Tumor · Sponsor: Yuhan Corporation
The goal of this YH42946-101 is to evaluate the safety, Tolerability, Pharmacokinetics and anti-tumor activity of YH42946 in patients with locally advanced of metastatic solid tumors with HER2 aberration and EGFR exon 20 insertions.
This description comes directly from the study's public registry record.
Yuhan Corporation Clinical Operation Team 1 · 8228280576 · clinicaltrials@yuhan.co.kr
Always discuss trial participation with your own doctor first.
| Next Oncology Virginia | Fairfax, Virginia, United States | Recruiting |
| Seoul National University Bundang Hospital | Seongnam-si, Gyeonggi-do, South Korea | Recruiting |
| The Catholic Univ. of Korea St. Vincent's Hospital | Suwon, Gyeonggi-do, South Korea | Recruiting |
| Chungbuk National University Hospital | Cheongju-si, North Chungcheong, South Korea | Recruiting |
| Seoul National University Hospital | Seoul, South Korea | Recruiting |
| Severance Hospital, Yonsei University | Seoul, South Korea | Recruiting |
| Samsung Medical Center | Seoul, South Korea | Recruiting |
| Asan Medical Center, University of Ulsan | Seoul, South Korea | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06616766